Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tim3”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT03961971
What this trial is testing

Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

Who this might be right for
Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 16
Early research (Phase 1)Study completedNCT03099109
What this trial is testing

LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors

Who this might be right for
Solid Tumor
Eli Lilly and Company 209
Not applicableStudy completedNCT05133505
What this trial is testing

Characterisation of TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System Diffuse Large B Cell Lymphomas

Who this might be right for
Lymphoma, B-Cell
University Hospital, Montpellier 65
Testing effectiveness (Phase 2)Active Not RecruitingNCT06056895
What this trial is testing

Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma

Who this might be right for
Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8Clinical Stage IV Merkel Cell Carcinoma AJCC v8Merkel Cell Carcinoma
University of Washington 12
Not applicableUnknownNCT02319876
What this trial is testing

Expression of TIM-3 on Lymphocytes in Sepsis

Who this might be right for
SepsisImmunosuppression
Changhai Hospital 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT04931654
What this trial is testing

Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

Who this might be right for
Carcinoma, Non-Small-Cell LungGastric CancerGastroesophageal Junction Cancer
AstraZeneca 136
Testing effectiveness (Phase 2)Study completedNCT04370704
What this trial is testing

Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

Who this might be right for
Melanoma
Incyte Corporation 61
Early research (Phase 1)WithdrawnNCT06290622
What this trial is testing

PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL

Who this might be right for
Diffuse Large B Cell LymphomaLymphoma, B-CellLymphoma, Follicular
University of Alabama at Birmingham
Testing effectiveness (Phase 2)WithdrawnNCT05367401
What this trial is testing

Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid Leukemia
Novartis Pharmaceuticals
Early research (Phase 1)Ended earlyNCT03752177
What this trial is testing

LY3415244 in Participants With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Eli Lilly and Company 12
Early research (Phase 1)Active Not RecruitingNCT02817633
What this trial is testing

TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Who this might be right for
Neoplasms
Tesaro, Inc. 463
Post-approval studies (Phase 4)UnknownNCT05294952
What this trial is testing

Co Ihibtory Receptor in Preeclampsia

Who this might be right for
Pre-Eclampsia
Assiut University 82
Large-scale testing (Phase 3)Ended earlyNCT04266301
What this trial is testing

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myelomonocytic, Chronic
Novartis Pharmaceuticals 530
Early research (Phase 1)Study completedNCT03708328
What this trial is testing

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

Who this might be right for
Solid TumorsMetastatic MelanomaNon-small Cell Lung Cancer (NSCLC)+2 more
Hoffmann-La Roche 134
Testing effectiveness (Phase 2)Active Not RecruitingNCT05287113
What this trial is testing

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Who this might be right for
Head and Neck Cancer
Incyte Biosciences International Sàrl 176
Not applicableLooking for participantsNCT05738980
What this trial is testing

Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3

Who this might be right for
Hepatocellular Carcinoma
Beijing Hospital 88
Testing effectiveness (Phase 2)Ended earlyNCT04586244
What this trial is testing

An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

Who this might be right for
Urothelial Carcinoma
Incyte Corporation 30
Testing effectiveness (Phase 2)Ended earlyNCT02608268
What this trial is testing

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Who this might be right for
Advanced Malignancies
Novartis Pharmaceuticals 252
Testing effectiveness (Phase 2)Study completedNCT04463771
What this trial is testing

Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

Who this might be right for
Endometrial Cancer
Incyte Corporation 206
Testing effectiveness (Phase 2)Looking for participantsNCT06125652
What this trial is testing

Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Who this might be right for
Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in Relapse
Xuzhou Medical University 20
Next Page